Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 4/20 | 0.57 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.57 |
| ▸ | PKM | P14618 | 2/20 | 0.57 |
| ▸ | ALPI | P09923 | 1/20 | 0.57 |
| ▸ | XIAP | P98170 | 1/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.53 |
| ▸ | USP2 | O75604 | 4/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.53 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | RECQL | P46063 | 2/20 | 0.53 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.53 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.53 |
| ▸ | EGFR | P00533 | 1/20 | 0.53 |
| ▸ | LCK | P06239 | 1/20 | 0.53 |
| ▸ | FYN | P06241 | 1/20 | 0.53 |
| ▸ | HTR2A | P28223 | 1/20 | 0.53 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.49 |
| ▸ | THRB | P10828 | 4/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7448572 | 1.00 | SLC7A5 (0.57) | SLC7A5PTGS1PKMALPIXIAP | |
| SCHEMBL31537504 | 0.88 | SLC7A5 (0.49) | SLC7A5PTGS1PKMALPIXIAP | |
| SCHEMBL22944380 | 0.88 | SLC7A5 (0.49) | SLC7A5PTGS1PKMALPIXIAP | |
| SCHEMBL10676768 | 0.84 | SLC7A5 (0.49) | SLC7A5PTGS1PKMALPIXIAP | |
| SCHEMBL5325945 | 0.84 | SLC7A5 (0.49) | SLC7A5PTGS1PKMALPIXIAP | |
| SCHEMBL14935980 | 0.82 | SLC7A5 (0.65) | SLC7A5PTGS1PKMALPIXIAP | |
| SCHEMBL29567654 | 0.82 | SLC7A5 (0.65) | SLC7A5PTGS1PKMALPIXIAP | |
| SCHEMBL44026 | 0.82 | SLC7A5 (0.65) | SLC7A5PTGS1PKMALPIXIAP | |
| SCHEMBL44027 | 0.82 | SLC7A5 (0.65) | SLC7A5PTGS1PKMALPIXIAP | |
| SCHEMBL29400795 | 0.82 | SLC7A5 (0.65) | SLC7A5PTGS1PKMALPIXIAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240382556-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF ALCOHOL DEPENDENCE | DUKE UNIVERSITY | 2024-11-21 | — | — | US | claimed |
| US-20220031798-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF OPIOID DEPENDENCE AND FOR THE TREATMENT OF PAIN | DUKE UNIVERSITY (US) | 2022-02-03 | — | — | US | claimed |
| WO-2015127558-A1 | METHODS AND USES FOR INDUCING OR FACILITATING MICTURITION IN A PATIENT IN NEED THEREOF | UNIVERSITé LAVAL (CA) | 2015-09-03 | — | — | WO | claimed |
| EP-0950046-A1 | 3,4-DISUBSTITUTED AZETIDIN-2-ONE DERIVATIVES USEFUL AS CYSTEINE PROTEINASE REGULATORS | SYNPHAR LABORATORIES INC. (CA) | 1999-10-20 | — | — | EP | claimed |
| WO-1998012176-A1 | 3,4-DISUBSTITUTED AZETIDIN-2-ONE DERIVATIVES USEFUL AS CYSTEINE PROTEINASE REGULATORS | SYNPHAR LABORATORIES INC. (US) | 1998-03-26 | — | — | WO | claimed |
| US-20260083759-A1 | Combinations Comprising Psychedelics for the Treatment of Schizophrenia and Other Neuropsychiatric and Neurologic Disorders | HADASIT MED RES SERVICE (IL) | 2026-03-26 | — | — | US | disclosed |
| US-12485115-B2 | Biased NMDA receptor modulators and uses thereof | EDWARD Via COLLEGE OF OSTEOPATHIC MEDICINE (US) | 2025-12-02 | — | — | US | disclosed |
| EP-4583858-A1 | COMBINATIONS COMPRISING PSYCHEDELICS FOR THE TREATMENT OF SCHIZOPHRENIA AND OTHER NEUROPSYCHIATRIC AND NEUROLOGIC DISORDERS | Hadasit Medical Research Services&Development Ltd. (IL) | 2025-07-16 | — | — | EP | disclosed |
| WO-2025099725-A1 | CONJUGATES AND USES THEREOF | HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD. (IL) | 2025-05-15 | — | — | WO | disclosed |
| WO-2025079064-A1 | INTERLEUKIN-17 PEPTIDOMIMETIC INHIBITORS | PEPTICOM LTD. (IL) | 2025-04-17 | — | — | WO | disclosed |
| US-20240382556-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF ALCOHOL DEPENDENCE | DUKE UNIVERSITY | 2024-11-21 | — | — | US | disclosed |
| WO-2024052895-A1 | COMBINATIONS COMPRISING PSYCHEDELICS FOR THE TREATMENT OF SCHIZOPHRENIA AND OTHER NEUROPSYCHIATRIC AND NEUROLOGIC DISORDERS | HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD (IL) | 2024-03-14 | — | — | WO | disclosed |
| US-20180142287-A1 | Compositions, Methods and Kits for Detection of Genetic Variants for Alzheimer's Disease | THE HONG KONG UNIVERSITY OF SCIENCE AND TECHNOLOGY (HK) | 2018-05-24 | — | — | US | disclosed |
| WO-2015127558-A1 | METHODS AND USES FOR INDUCING OR FACILITATING MICTURITION IN A PATIENT IN NEED THEREOF | UNIVERSITé LAVAL (CA) | 2015-09-03 | — | — | WO | disclosed |
| US-20080096870-A1 | Methods and Materials for Treating Mental Illness | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. | 2008-04-24 | — | — | US | disclosed |
| EP-1778211-A1 | METHODS AND MATERIALS FOR TREATING MENTAL ILLNESS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2007-05-02 | — | — | EP | disclosed |
| WO-2006020171-A1 | METHODS AND MATERIALS FOR TREATING MENTAL ILLNESS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2006-02-23 | — | — | WO | disclosed |
| EP-0950046-A1 | 3,4-DISUBSTITUTED AZETIDIN-2-ONE DERIVATIVES USEFUL AS CYSTEINE PROTEINASE REGULATORS | SYNPHAR LABORATORIES INC. (CA) | 1999-10-20 | — | — | EP | disclosed |
| WO-1998012176-A1 | 3,4-DISUBSTITUTED AZETIDIN-2-ONE DERIVATIVES USEFUL AS CYSTEINE PROTEINASE REGULATORS | SYNPHAR LABORATORIES INC. (US) | 1998-03-26 | — | — | WO | disclosed |
| US-4766121-A | NOT AFFECTING THE HEART | SMITH KLINE & FRENCH LABORATORIES LTD. (GB) | 1988-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260083759-A1 | Combinations Comprising Psychedelics for the Treatment of Schizophrenia and Other Neuropsychiatric and Neurologic Disorders | BDNF, NTRK2, GRIN2A | SLC7A5 3582/4885PTGS1 3978/4885PKM 3100/4885 |
| US-20240382556-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF ALCOHOL DEPENDENCE | GRIN3A, GRIN1, GRIN2A | SLC7A5 1802/4885PTGS1 706/4885PKM 1484/4885 |
| US-20220031798-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF OPIOID DEPENDENCE AND FOR THE TREATMENT OF PAIN | OPRL1, OPRK1, OPRM1 | SLC7A5 1778/4885PTGS1 839/4885PKM 1745/4885 |
| US-12485115-B2 | Biased NMDA receptor modulators and uses thereof | GRIN1, GRIN2A, GRIN3A | SLC7A5 3119/4885PTGS1 2919/4885PKM 908/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.